Click
here to close Hello! We notice that
you are using Internet Explorer, which is not supported by Echinobase
and may cause the site to display incorrectly. We suggest using a
current version of Chrome,
FireFox,
or Safari.
Transl Lung Cancer Res
2014 Apr 01;32:70-4. doi: 10.3978/j.issn.2218-6751.2014.02.02.
Show Gene links
Show Anatomy links
Concordance of IHC, FISH and RT-PCR for EML4-ALK rearrangements.
Teixidó C
,
Karachaliou N
,
Peg V
,
Gimenez-Capitan A
,
Rosell R
.
Abstract
The echinoderm microtubule-associated protein-like 4 anaplastic lymphoma kinase (EML4-ALK) has emerged as the second most important driver oncogene in lung cancer and the first targetable fusion oncokinase to be identified in 4-6% of lung adenocarcinomas. Crizotinib, along with a diagnostic test-the Vysis ALK Break Apart fluorescence in situ hybridization (FISH) Probe Kit-is approved for the treatment of ALK positive advanced non-small cell lung cancer (NSCLC). However, the success of a targeted drug is critically dependent on a sensitive and specific screening assay to detect the molecular drug target. In our experience, reverse transcription polymerase chain reaction (RT-PCR)-based detection of EML4-ALK is a more sensitive and reliable approach compared to FISH and immunohistochemistry (IHC). Although ALK FISH is clinically validated, the assay can be technically challenging and other diagnostic modalities, including IHC and RT-PCR should be further explored.
Camidge,
Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study.
2012, Pubmed
Camidge,
Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study.
2012,
Pubmed
Camidge,
Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment.
2010,
Pubmed
Chabner,
Early accelerated approval for highly targeted cancer drugs.
2011,
Pubmed
Chihara,
More on crizotinib.
2011,
Pubmed
Conklin,
Immunohistochemistry is a reliable screening tool for identification of ALK rearrangement in non-small-cell lung carcinoma and is antibody dependent.
2013,
Pubmed
Hallberg,
Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology.
2013,
Pubmed
Heuckmann,
Differential protein stability and ALK inhibitor sensitivity of EML4-ALK fusion variants.
2012,
Pubmed
Inamura,
EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers.
2008,
Pubmed
,
Echinobase
Karachaliou,
Optimal detection of ALK rearranged lung adenocarcinomas.
2013,
Pubmed
Keedy,
American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) Mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy.
2011,
Pubmed
Kwak,
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.
2010,
Pubmed
Lee,
Testing for anaplastic lymphoma kinase rearrangement to target crizotinib therapy: oncology, pathology and health economic perspectives.
2013,
Pubmed
Li,
Large-scale screening and molecular characterization of EML4-ALK fusion variants in archival non-small-cell lung cancer tumor specimens using quantitative reverse transcription polymerase chain reaction assays.
2014,
Pubmed
,
Echinobase
Martinez,
Fluorescence in situ hybridization and immunohistochemistry as diagnostic methods for ALK positive non-small cell lung cancer patients.
2013,
Pubmed
Paik,
Clinicopathologic implication of ALK rearrangement in surgically resected lung cancer: a proposal of diagnostic algorithm for ALK-rearranged adenocarcinoma.
2012,
Pubmed
Park,
Immunohistochemical screening for anaplastic lymphoma kinase (ALK) rearrangement in advanced non-small cell lung cancer patients.
2012,
Pubmed
Riely,
Incorporation of crizotinib into the NCCN guidelines.
2011,
Pubmed
Rodig,
Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population.
2009,
Pubmed
Savic,
Detection of ALK-positive non-small-cell lung cancers on cytological specimens: high accuracy of immunocytochemistry with the 5A4 clone.
2013,
Pubmed
Shaw,
Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.
2013,
Pubmed
Shaw,
Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK.
2009,
Pubmed
Sholl,
Combined use of ALK immunohistochemistry and FISH for optimal detection of ALK-rearranged lung adenocarcinomas.
2013,
Pubmed
Soda,
Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.
2007,
Pubmed
,
Echinobase
Tanizaki,
Combined effect of ALK and MEK inhibitors in EML4-ALK-positive non-small-cell lung cancer cells.
2012,
Pubmed
,
Echinobase
Thunnissen,
EML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendations.
2012,
Pubmed
Tuononen,
Targeted resequencing reveals ALK fusions in non-small cell lung carcinomas detected by FISH, immunohistochemistry, and real-time RT-PCR: a comparison of four methods.
2013,
Pubmed
Wallander,
Comparison of reverse transcription-polymerase chain reaction, immunohistochemistry, and fluorescence in situ hybridization methodologies for detection of echinoderm microtubule-associated proteinlike 4-anaplastic lymphoma kinase fusion-positive non-small cell lung carcinoma: implications for optimal clinical testing.
2012,
Pubmed
,
Echinobase
Weickhardt,
Diagnostic assays for identification of anaplastic lymphoma kinase-positive non-small cell lung cancer.
2013,
Pubmed
Yi,
Detection of anaplastic lymphoma kinase (ALK) gene rearrangement in non-small cell lung cancer and related issues in ALK inhibitor therapy: a literature review.
2012,
Pubmed
Zhang,
Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression.
2010,
Pubmed
